News Releases

Year

26 Jul '21

Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021

New GAIN Trial baseline data demonstrates majority of patients have elevated Von Willebrand factor and alpha-2-macroglobulin Cortexyme to host AAIC symposium titled “Getting to the Root Cause of Alzheimer’s Disease: An Innovative, Upstream Approach for Disease Modification” on Tuesday, July 27

PDF Version

23 Jul '21

Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 23, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the

PDF Version

22 Jul '21

Cortexyme to Present New Data at AAIC 2021

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 22, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases , announced that it

PDF Version

21 Jul '21

Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021

Leading drug candidate penetrates and disrupts bacterial biofilms, a key feature for efficacy in treating P. gingivalis driven disease Atuzaginstat reverses alveolar bone loss in mice after oral P. gingivalis infection at doses relevant for therapeutic efficacy in periodontal disease SOUTH SAN

PDF Version

19 Jul '21

Cortexyme to Host Symposium at AAIC 2021

“Getting to the Root Cause of Alzheimer’s Disease: An Innovative, Upstream Approach for Disease Modification” SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 19, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the

PDF Version

08 Jul '21

Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat

Part 1 to be held Friday July 23 at 10:00 a.m. ET : Innovation in Periodontal Disease – A Major Unmet Medical Need Part 2 to be held Friday July 30 at 10:00 a.m. ET : Innovation in Alzheimer's Disease – Getting to the Root Cause of Neurodegeneration SOUTH SAN FRANCISCO, Calif.

PDF Version

01 Jun '21

Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting

Baseline demographic and biomarker data reinforce appropriate patient population enrolled ahead of top-line data expected in fourth quarter 2021 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 1, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease

PDF Version

26 May '21

Cortexyme to Present at Investor Conferences in June 2021

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris

PDF Version

10 May '21

Cortexyme Provides Business Update and Reports First Quarter 2021 Results

Top-line data from 643-subject Alzheimer’s disease pivotal GAIN Trial expected in fourth quarter 2021 Top-line data from 233-subject periodontal disease Phase 2 REPAIR sub-study of the GAIN Trial expected in fourth quarter 2021 COR588 on track to initiate first-in-human studies in third quarter

PDF Version

04 May '21

Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 4, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Chris

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 16